DIVISLAB Stock Overview
Divi's Laboratories Limited manufactures and sells generic active pharmaceutical ingredients (APIs) and intermediates, and nutraceutical ingredients in India, the United States, Asia, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
My Notes
NewNotes are coming soon
Divi's Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹2,750.85 |
| 52 Week High | ₹4,640.80 |
| 52 Week Low | ₹2,740.10 |
| Beta | 0.21 |
| 1 Month Change | -19.91% |
| 3 Month Change | -16.61% |
| 1 Year Change | -35.69% |
| 3 Year Change | 28.13% |
| 5 Year Change | 165.40% |
| Change since IPO | 31,115.32% |
Recent News & Updates
Recent updates
Is Now The Time To Put Divi's Laboratories (NSE:DIVISLAB) On Your Watchlist?
Nov 08
Divi's Laboratories (NSE:DIVISLAB) Is Increasing Its Dividend To ₹30.00
Aug 04Divi's Laboratories' (NSE:DIVISLAB) Shareholders Will Receive A Bigger Dividend Than Last Year
Jul 21Divi's Laboratories (NSE:DIVISLAB) Will Pay A Larger Dividend Than Last Year At ₹30.00
Jul 07Here's Why We Think Divi's Laboratories (NSE:DIVISLAB) Might Deserve Your Attention Today
Jul 03Does Divi's Laboratories (NSE:DIVISLAB) Deserve A Spot On Your Watchlist?
Apr 03Should You Be Adding Divi's Laboratories (NSE:DIVISLAB) To Your Watchlist Today?
Dec 23With EPS Growth And More, Divi's Laboratories (NSE:DIVISLAB) Is Interesting
Sep 02Here's Why We Think Divi's Laboratories (NSE:DIVISLAB) Is Well Worth Watching
Mar 25Do Institutions Own Divi's Laboratories Limited (NSE:DIVISLAB) Shares?
Mar 10Who Has Been Selling Divi's Laboratories Limited (NSE:DIVISLAB) Shares?
Feb 23Is Divi's Laboratories' (NSE:DIVISLAB) Share Price Gain Of 216% Well Earned?
Jan 25
Is Divi's Laboratories Limited's(NSE:DIVISLAB) Recent Stock Performance Tethered To Its Strong Fundamentals?
Jan 07Is Now The Time To Put Divi's Laboratories (NSE:DIVISLAB) On Your Watchlist?
Dec 20What Type Of Shareholders Own The Most Number of Divi's Laboratories Limited (NSE:DIVISLAB) Shares?
Dec 03Divi's Laboratories Limited (NSE:DIVISLAB) Not Flying Under The Radar
Jul 30Should You Or Shouldn't You: A Dividend Analysis on Divi's Laboratories Limited (NSE:DIVISLAB)
Jul 17Are Divi's Laboratories's (NSE:DIVISLAB) Statutory Earnings A Good Guide To Its Underlying Profitability?
Jul 04Shareholder Returns
| DIVISLAB | IN Life Sciences | IN Market | |
|---|---|---|---|
| 7D | -17.0% | -13.2% | -0.8% |
| 1Y | -35.7% | -28.3% | -2.4% |
Return vs Industry: DIVISLAB underperformed the Indian Life Sciences industry which returned -28.3% over the past year.
Return vs Market: DIVISLAB underperformed the Indian Market which returned -2.4% over the past year.
Price Volatility
| DIVISLAB volatility | |
|---|---|
| DIVISLAB Average Weekly Movement | 4.5% |
| Life Sciences Industry Average Movement | 5.1% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 3.4% |
Stable Share Price: DIVISLAB is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: DIVISLAB's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 16,543 | Kiran Divi | https://www.divislabs.com |
Divi's Laboratories Limited manufactures and sells generic active pharmaceutical ingredients (APIs) and intermediates, and nutraceutical ingredients in India, the United States, Asia, Europe, and internationally. It also undertakes custom synthesis of APIs and intermediates; and supplies a range of carotenoids, as well as markets vitamins to nutritional, pharma, food/beverage, and feed industries. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994.
Divi's Laboratories Limited Fundamentals Summary
| DIVISLAB fundamental statistics | |
|---|---|
| Market Cap | ₹730.26b |
| Earnings (TTM) | ₹23.97b |
| Revenue (TTM) | ₹83.35b |
30.5x
P/E Ratio8.8x
P/S RatioIs DIVISLAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DIVISLAB income statement (TTM) | |
|---|---|
| Revenue | ₹83.35b |
| Cost of Revenue | ₹32.58b |
| Gross Profit | ₹50.77b |
| Other Expenses | ₹26.80b |
| Earnings | ₹23.97b |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 90.30 |
| Gross Margin | 60.91% |
| Net Profit Margin | 28.76% |
| Debt/Equity Ratio | 0.03% |
How did DIVISLAB perform over the long term?
See historical performance and comparison